Related Experiment Videos
Interleukin-1: biological effects in human hematopoiesis
J Crown1, A Jakubowski, J Gabrilove
1Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Leukemia & Lymphoma
|April 1, 1993
Summary
Interleukin-1 (IL-1) showed potential in a phase I trial for cancer patients, inducing neutrophilia and thrombocytosis. While not statistically significant, IL-1 may help reduce neutropenia following chemotherapy.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Interleukin-1 (IL-1) significantly impacts hematopoiesis, stimulating progenitor cells and cytokine production.
- IL-1 shows promise in mitigating chemotherapy-induced myelosuppression.
- Recombinant human IL-1 is undergoing clinical evaluation.
Purpose of the Study:
- To evaluate the safety and hematologic effects of IL-1 beta in cancer patients.
- To assess IL-1 beta's efficacy in reducing myelosuppression following 5-fluorouracil (5-FU) chemotherapy.
Main Methods:
- A phase I clinical trial was conducted.
- Participants received IL-1 beta alone or after a myelosuppressive dose of 5-FU.
- Hematologic parameters, including neutropenia and thrombocytosis, were monitored.
Main Results:
- IL-1 beta administration resulted in rapid neutrophilia and subsequent thrombocytosis.
- Hypotension was identified as a dose-limiting toxicity.
- A trend towards reduced neutropenia duration was observed with IL-1 beta plus 5-FU, but it lacked statistical significance.
Conclusions:
- IL-1 beta demonstrates notable hematologic effects in cancer patients.
- Further research is warranted to confirm IL-1's protective role against chemotherapy-induced myelosuppression.
- Combinations of IL-1 with growth factors may offer synergistic hematologic benefits.